VCS
ABBV icon

Vaughan & Co Securities’s AbbVie ABBV Stock Holding History

Vaughan & Co Securities’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$660K Sell
2,622
-119
-4% -$25.6K 0.31% 35
2026
Q1 		$596K Sell
2,741
-59
-2% -$13.1K 0.31% 41
2025
Q4 		$640K Sell
2,800
-137
-5% -$31.2K 0.33% 37
2025
Q3 		$680K Sell
2,937
-588
-17% -$120K 0.36% 35
2025
Q2 		$654K Sell
3,525
-6
-0.2% -$1.11K 0.38% 31
2025
Q1 		$740K Sell
3,531
-57
-2% -$11.1K 0.46% 27
2024
Q4 		$638K Sell
3,588
-14
-0.4% -$2.57K 0.38% 37
2024
Q3 		$711K Sell
3,602
-13
-0.4% -$2.43K 0.42% 36
2024
Q2 		$620K Buy
3,615
+38
+1% +$6.29K 0.39% 39
2024
Q1 		$651K Sell
3,577
-390
-10% -$67.2K 0.41% 30
2023
Q4 		$615K Sell
3,967
-87
-2% -$12.7K 0.41% 39
2023
Q3 		$604K Sell
4,054
-15
-0.4% -$2.2K 0.45% 29
2023
Q2 		$548K Sell
4,069
-20
-0.5% -$2.93K 0.39% 42
2023
Q1 		$652K Sell
4,089
-1,008
-20% -$154K 0.48% 33
2022
Q4 		$824K Sell
5,097
-197
-4% -$30.2K 0.66% 23
2022
Q3 		$711K Sell
5,294
-74
-1% -$10.6K 0.61% 21
2022
Q2 		$822K Hold
5,368
– – 0.66% 17
2022
Q1 		$870K Sell
5,368
-59
-1% -$8.57K 0.6% 20
2021
Q4 		$735K Hold
5,427
– – 0.5% 27
2021
Q3 		$585K Hold
5,427
– – 0.44% 35
2021
Q2 		$611K Hold
5,427
– – 0.45% 32
2021
Q1 		$587K Sell
5,427
-1,727
-24% -$185K 0.47% 34
2020
Q4 		$767K Sell
7,154
-358
-5% -$34.4K 0.68% 13
2020
Q3 		$658K Sell
7,512
-185
-2% -$17.4K 0.69% 12
2020
Q2 		$756K Sell
7,697
-143
-2% -$12.6K 0.83% 11
2020
Q1 		$597K Sell
7,840
-68
-0.9% -$5.79K 0.76% 11
2019
Q4 		$700K Buy
+7,908
New +$657K 0.63% 17

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vaughan & Co Securities's ABBV Position: Q2 2026 in Review

Vaughan & Co Securities reduced its AbbVie (ABBV) stake by 4.3% in Q2 2026, selling an estimated $25.6K and leaving 2,622 shares worth $660K. The position accounts for 0.31% of the portfolio, ranked #35.

Vaughan & Co Securities first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. The position peaked at $870K in Q1 2022. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Vaughan & Co Securities held 2,622 shares of AbbVie worth $660K as of Q2 2026.
  • Vaughan & Co Securities sold 119 AbbVie shares in Q2 2026, an estimated $25.6K.
  • AbbVie made up 0.31% of Vaughan & Co Securities's portfolio in Q2 2026, its #35 holding.
  • Vaughan & Co Securities first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • Vaughan & Co Securities's AbbVie position peaked at $870K in Q1 2022.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Vaughan & Co Securities's 13F filing for Q2 2026, filed 3 Aug 2026.